Last Updated: 19/11/2014
A cross sectional survey to assess glucose-6-phosphate dehydrogenase deficiency in three different regions of Mozambique
Objectives
This study aimed to assess the prevalence G6PD deficiency in three different and geographically distinct districts of Mozambique, quantify the levels of enzymatic activity in these populations, and identify risk factors associated to G6PDd.
The main safety concern of primaquine is the risk of haemolytic anaemia in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals. Countries aiming for malaria elimination through community interventions, such as Mass Drug Administration (MDA) using primaquine, need to obtain accurate G6PDd prevalence data in order to better inform potential elimination strategies. In Mozambique, G6PD deficiency prevalence is largely unknown, with an estimated national prevalence of 10%.
School-based cross-sectional survey
Jan 2015 — Dec 2015
Related Resources
